View Item 

Show simple item record

A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting

dc.contributor.authorRosenberg, M. T.en_US
dc.contributor.authorStaskin, D. R.en_US
dc.contributor.authorKaplan, S. A.en_US
dc.contributor.authorMacDiarmid, S. A.en_US
dc.contributor.authorNewman, Diane Kaschaken_US
dc.contributor.authorOhl, Dana A.en_US
dc.date.accessioned2010-06-01T22:34:31Z
dc.date.available2010-06-01T22:34:31Z
dc.date.issued2007-09en_US
dc.identifier.citationRosenberg, M. T.; Staskin, D. R.; Kaplan, S. A.; MacDiarmid, S. A.; Newman, D. K.; Ohl, D. A. (2007). "A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting." International Journal of Clinical Practice 61(9): 1535-1546. <http://hdl.handle.net/2027.42/75555>en_US
dc.identifier.issn1368-5031en_US
dc.identifier.issn1742-1241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75555
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17627768&dopt=citationen_US
dc.format.extent635018 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal compilation 2007 Blackwell Publishing Ltden_US
dc.titleA practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care settingen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumMid-Michigan Health Centers, Department of Family Medicine, Foote Health System, Jackson, MI, USA, President, Urologic Health Foundationen_US
dc.contributor.affiliationumDivision of Andrology and Microsurgery, University of Michigan, Ann Arbor, MI, USA, Secretary/Treasurer, Urologic Health Foundationen_US
dc.contributor.affiliationotherWeill Medical College of Cornell University, Female Urology and Voiding Dysfunction, New York-Presbyterian Hospital, New York, NY, USAen_US
dc.contributor.affiliationotherInstitute of Bladder and Prostate Health, Weill Cornell Medical College, New York, NY, USAen_US
dc.contributor.affiliationotherBladder Control and Pelvic Pain Center, Greensboro, NC, USAen_US
dc.contributor.affiliationotherPenn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Medical Center, Philadelphia, PA, USAen_US
dc.identifier.pmid17627768en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75555/1/j.1742-1241.2007.01491.x.pdf
dc.identifier.doi10.1111/j.1742-1241.2007.01491.xen_US
dc.identifier.sourceInternational Journal of Clinical Practiceen_US
dc.identifier.citedreferenceHyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166: 550 – 3.en_US
dc.identifier.citedreferenceVan Venrooij GE, Van Melick HH, Eckhardt MD et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002; 168: 605 – 9.en_US
dc.identifier.citedreferenceKaplan SA, Ikeguchi EF, Santarosa RP et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996; 47: 836 – 9.en_US
dc.identifier.citedreferenceFawzy A, Fontenot C, Guthrie R et al. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med 1997; 29: 321 – 5.en_US
dc.identifier.citedreferenceAbrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37 – 49.en_US
dc.identifier.citedreferenceDennis L, Griffiths K, Khoury S et al. Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy C, Yoshida O. eds. Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia. London: Health Publications, Ltd., 1998: 669 – 84.en_US
dc.identifier.citedreferenceLee C, Cockett A, Cussenot K et al. Regulation of prostate growth. In: Chatelain C, Denis L, Foo KT, Khoury S, McConnell J. eds. Proceedings of the Fifth International Consultation of Benign Prostatic Hyperplasia, Chapter 3. London: Health Publications, Ltd., 2001: 79 – 106.en_US
dc.identifier.citedreferenceAbrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 187: 167 – 78.en_US
dc.identifier.citedreferenceOuslander JG. Management of overactive bladder. N Engl J Med 2004; 350: 786 – 99.en_US
dc.identifier.citedreferenceWein AJ. Pathophysiology and categorization of voiding dysfunction. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology, 9th edn. Philadelphia, PA: Saunders Elsevier, 2007: 1973 – 85.en_US
dc.identifier.citedreferenceChapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 335 – 40.en_US
dc.identifier.citedreferenceJaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 2005; 6: 410 – 8.en_US
dc.identifier.citedreferenceStewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327 – 36.en_US
dc.identifier.citedreferenceBerry SJ, Coffee DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474 – 9.en_US
dc.identifier.citedreferenceWei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256 – 61.en_US
dc.identifier.citedreferenceRosenberg M. The sad, misunderstood prostate: understanding perceptions and reality. Int J Clin Pract 2006; 60: 1148 – 9.en_US
dc.identifier.citedreferenceJacobsen SJ, Girman CJ, Guess HA et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995; 155: 477 – 81.en_US
dc.identifier.citedreferenceO'Conor RM, Johannesson M, Hass SL et al. Urge incontinence. Quality of life and patients’ valuation of symptom reduction. Pharmacoeconomics 1998; 14: 531 – 9.en_US
dc.identifier.citedreferenceBruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol 2003; 5: 72 – 80.en_US
dc.identifier.citedreferenceNickel JC. BPH: costs and treatment outcomes. Am J Manag Care 2006; 12 ( Suppl. 5 ): S141 – 8.en_US
dc.identifier.citedreferenceMcGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001; 7 ( Suppl. 2 ): S62 – 75.en_US
dc.identifier.citedreferenceHaidinger G, Temml C, Schatzl G et al. Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology. Eur Urol 2000; 37: 413 – 20.en_US
dc.identifier.citedreferenceGades NM, Jacobson DJ, Girman CJ et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 2005; 95: 549 – 53.en_US
dc.identifier.citedreferenceSpeakman MJ, Kirby RS, Joyce A et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004; 93: 985 – 90.en_US
dc.identifier.citedreferencevan Kerrebroeck P, Abrams P, Chaikin D et al. for the Standardisation Sub-committee of the International Continence Society. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 179 – 83.en_US
dc.identifier.citedreferenceRoehrborn CG, McConnell JD, Barry MJ. Guidelines on the Management of Benign Prostatic Hyperplasia. Linthicum, MD: American Urological Association, Education and Research, Inc., 2003.en_US
dc.identifier.citedreferenceBarry MJ, Fowler FJ Jr, O'Leary MP et al. and the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549 – 57.en_US
dc.identifier.citedreferenceNaslaund MJ, Costa FJ, Miner MM. Managing enlarged prostate in primary care. Int J Clin Pract 2006; 60: 1609 – 15.en_US
dc.identifier.citedreferenceSuzuki S, Platz EA, Kawachi I et al. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 2002; 75: 689 – 97.en_US
dc.identifier.citedreferenceRohrmann S, Giovannucci E, Willett WC et al. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr 2007; 85: 523 – 9.en_US
dc.identifier.citedreferenceMiner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006; 28: 13 – 25.en_US
dc.identifier.citedreferenceLepor H, Williford WO, Barry MJ et al. for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veteran Affairs Cooperative Studies Benign Hyperplasia Study Group. J Urol 1998; 160: 1358 – 67.en_US
dc.identifier.citedreferenceLowe FC. Role of the newer alpha, -adrenergic receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004; 26: 1701 – 13.en_US
dc.identifier.citedreferenceKirby RS. Doxazosin in benign prostatic hyperplasia. Effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46: 182 – 6.en_US
dc.identifier.citedreferenceKirby RS. Terazosin in benign prostatic hyperplasia. Effects on blood pressure in normotensive and hypertensive men. Br J Urol 1998; 82: 373 – 9.en_US
dc.identifier.citedreferenceKaplan SA. Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol 2006; 8 ( Suppl. 4 ): S10 – 7.en_US
dc.identifier.citedreferenceMcConnell JD, Roehrborn CG, Bautista OM et al. for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387 – 98.en_US
dc.identifier.citedreferenceAbrams P, Kaplan S, De Koning Gans HJ et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999 – 1004.en_US
dc.identifier.citedreferenceMcNeill SA, Hargreave TB, Geffriaud-Ricouard C et al. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies alfuzosin. Urology 2001; 57: 459 – 65.en_US
dc.identifier.citedreferenceKolman C, Girman CJ, Jacobsen SJ et al. Distribution of post-void residual urine in randomly selected men. J Urol 1999; 161: 122 – 7.en_US
dc.identifier.citedreferenceGoode PS, Locher JL, Bryant RL et al. Measurement of postvoid residual urine with portable transabdominal bladder ultrasound scanner and urethral catheterization. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11: 296 – 300.en_US
dc.identifier.citedreferenceCoombes GM, Millard RJ. The accuracy of portable ultrasound scanning in the measurement of residual urine volume. J Urol 1994; 152 ( 6 part 1 ): 2083 – 5.en_US
dc.identifier.citedreferenceByun SS, Kim HH, Lee E et al. Accuracy of bladder volume determinations by ultrasonography: are they accurate over entire bladder volume range? Urology 2003; 62: 656 – 60.en_US
dc.identifier.citedreferenceOckrim JL, Laniado ME, Patel A et al. A probability based system for combining simple office parameters as a predictor of bladder outflow obstruction. J Urol 2001; 166: 2221 – 5.en_US
dc.identifier.citedreferenceAbrams P. Urodynamics, 3rd edn. London, England: Springer, 2005.en_US
dc.identifier.citedreferenceBurgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatric Soc 2000; 48: 370 – 4.en_US
dc.identifier.citedreferenceAndersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004; 3: 46 – 53.en_US
dc.identifier.citedreferenceSteers W, Corcos J, Foote J et al. An investigation of dose titration with darifenacin, an M 3 -selective receptor antagonist. BJU Int 2005; 95: 580 – 6.en_US
dc.identifier.citedreferenceChapple CR, Martinez-Garcia R, Selvaggi L et al. for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464 – 70.en_US
dc.identifier.citedreferenceBlake-James BT, Rashidian A, Ikeda Y et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2006; 99: 85 – 96.en_US
dc.identifier.citedreferenceLee JY, Kim HW, Lee SJ et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and overactive bladder. BJU Int 2004; 94: 817 – 20.en_US
dc.identifier.citedreferenceKaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273 – 6.en_US
dc.identifier.citedreferenceKaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006; 60: 1157 – 65.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1742-1241.2007.01491.x.pdf
Size:
620.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.